Market Overview

Merck Strikes $773M Deal For Privately Held Tilos Therapeutics

Share:
Merck Strikes $773M Deal For Privately Held Tilos Therapeutics

Keeping in line with the biotech M&A frenzy seen for much of the year, Merck & Co., Inc. (NYSE: MRK) announced a deal Monday to buy Tilos Therapeutics.

Only recently, the pharma giant agreed to buy Peloton Therapeutics in a deal valued at up to $2.2 billion.

What Happened

Merck struck an agreement to buy privately held Tilos, which develops therapies targeting the latent transforming growth factor — or TGT-beta — complex for treating cancer, fibrosis and autoimmune diseases, for up to $773 million, including an upfront payment as well as contingent milestone payments.

"Tilos has developed a compelling portfolio of candidates that employ a novel approach to modulating the potent signaling molecule TGF-beta by binding to latency-associated peptide, with potential applications across a range of disease indications," Dean Li, senior vice president for discovery and translational medicine at Merck Research Laboratories, said in a statement. 

Why It's Important

TGF-beta inhibitors are antibodies that target a protein called latency-associated peptide, and could come in handy to break the in-built or acquired resistance to checkpoint inhibitors such as Merck's Keytruda. They are therefore termed immunotherapy boosters.

A TGF-beta inhibitor when paired with Keytruda can help a patient's immune system track a tumor it might have missed previously.

Merck shares were trading up slightly at $82.49 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers

Posted-In: Tilos TherapeuticsBiotech M&A News Trading Ideas Best of Benzinga

 

Related Articles (MRK)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Tilson Says Wait For The Bust In Cannabis Stocks, Calls Bitcoin A 'Pure Speculative Investment'

Investor Movement Index Summary: May 2019